Shares of Innophos Holdings, Inc. (NASDAQ:IPHS) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating. Innophos’ rating score has improved by 50% in the last three months as a result of various analysts’ ratings changes.
Brokers have set a 12-month consensus price target of $46.00 for the company and are predicting that the company will post $0.53 EPS for the current quarter, according to Zacks. Zacks has also given Innophos an industry rank of 220 out of 255 based on the ratings given to its competitors.
Several equities analysts have issued reports on IPHS shares. BidaskClub lowered Innophos from a “buy” rating to a “hold” rating in a report on Thursday, October 10th. Zacks Investment Research raised Innophos from a “sell” rating to a “hold” rating in a report on Wednesday, October 9th. Finally, ValuEngine raised Innophos from a “sell” rating to a “hold” rating in a report on Saturday, September 14th.
Hedge funds have recently modified their holdings of the business. Laurion Capital Management LP purchased a new position in shares of Innophos during the second quarter worth about $201,000. JPMorgan Chase & Co. grew its holdings in shares of Innophos by 8.5% during the second quarter. JPMorgan Chase & Co. now owns 68,912 shares of the specialty chemicals company’s stock worth $1,965,000 after buying an additional 5,371 shares during the last quarter. Aperio Group LLC grew its holdings in shares of Innophos by 1.7% during the second quarter. Aperio Group LLC now owns 38,543 shares of the specialty chemicals company’s stock worth $1,122,000 after buying an additional 652 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Innophos during the second quarter worth about $132,000. Finally, Invesco Ltd. grew its holdings in shares of Innophos by 7.9% during the second quarter. Invesco Ltd. now owns 131,031 shares of the specialty chemicals company’s stock worth $3,814,000 after buying an additional 9,600 shares during the last quarter. 93.65% of the stock is currently owned by institutional investors.
NASDAQ:IPHS opened at $32.16 on Wednesday. The firm has a market capitalization of $631.06 million, a PE ratio of 14.11 and a beta of 1.44. The business’s fifty day moving average price is $32.01 and its 200 day moving average price is $29.63. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.85 and a quick ratio of 1.41. Innophos has a 12 month low of $22.57 and a 12 month high of $37.53.
Innophos (NASDAQ:IPHS) last posted its earnings results on Tuesday, August 6th. The specialty chemicals company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.37 by $0.06. The firm had revenue of $185.04 million for the quarter, compared to analyst estimates of $196.55 million. Innophos had a return on equity of 12.35% and a net margin of 3.79%. Innophos’s revenue for the quarter was down 10.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.55 earnings per share. As a group, equities analysts anticipate that Innophos will post 2.18 EPS for the current year.
Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.
Further Reading: How much can an individual set aside as a catch-up contribution?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.